# A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

> **NCT00454896** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 739 (actual)

## Conditions studied

- Urinary Bladder, Overactive

## Interventions

- **DRUG:** VESIcare®
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00454896
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2005-09
- **Final completion:** 2005-09
- **Target enrollment:** 739 (ACTUAL)
- **Last updated:** 2014-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00454896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00454896, "A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00454896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*